Overexpression of p53 in transitional cell carcinoma of the renal pelvis and ureter relation to tumor proliferation and survival

Cancer

Volumn 79, Issue 11, 1997, Pages 2178-2185

  Rey, Agustín ^a   Lara, Pedro C ^a   Redondo, Elena ^a   Valdés, Estíbaliz ^b   Apolinario, Rosa ^a  

^a Hospital Nuestra Senora del Pino   (Spain)

^b NONE

Author keywords

p53; renal pelvis and ureter; transitional cell carcinoma; tumor proliferation

Indexed keywords

KI 67 ANTIGEN; PROTEIN P53;

ADULT; AGED; ARTICLE; CELL PROLIFERATION; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; KIDNEY PELVIS; MAJOR CLINICAL STUDY; MALE; PREDICTION; PRIORITY JOURNAL; PROTEIN EXPRESSION; RISK ASSESSMENT; SURVIVAL TIME; TRANSITIONAL CELL CARCINOMA; URETER;

ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, TRANSITIONAL CELL; CELL DIVISION; FEMALE; HUMANS; KIDNEY NEOPLASMS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PROGNOSIS; SURVIVAL ANALYSIS; TUMOR SUPPRESSOR PROTEIN P53; URETERAL NEOPLASMS;

EID: 0030957080     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0142(19970601)79:11<2178::AID-CNCR16>3.0.CO;2-T     Document Type: Article

References (37)

1. Mellemgaard A, Carstensen B, Norgaard N, Knudsen JB, Olsen JH. Trends in the incidence of cancer of the kidney, pelvis, ureter and bladder in Denmark. 1943-1988. Scand J Urol Nephrol 1993;27:327-32.
2. Devessa SS, Silverman DT, McLaughlin JK. Comparison of the descriptive epidemiology of urinary tract cancers. Cancer Causes Control 1990;1:133-41.
3. Davis BW, Hough AJ, Gardener WA. Renal pelvis carcinoma: morphological correlates of metastaic behavior. J Urol 1987;138:280-5.
4. Batata MA, Whitmore WF, Hilaris BS, Tokita N, Grabstald H. Primary carcinoma of the ureter: a prognostic study. Cancer 1975;35:1626-32.
5. Melamed MR, Reuter VE. Pathology and staging of urothelial tumors of the kidney and the ureter. Urol Clin North Am 1993;20:333-47.
6. Highman WJ. Transitional carcinoma of the upper urinary tract. A histological and cytopathological study. J Clin Pathol 1986;39:297-305.
7. Corrado F, Mannini D, Ferri C, Corrado G, Bertoni F, Bacchini P, et al. The prognostic significance of DNA ploidy pattern in transitional cell cancer of the renal pelvis and ureter: continuing follow-up. Eur Urol 1992;21:48-50.
8. el-Abadi H, Nagel R. Transitional cell carcinoma of the renal pelvis and ureter: prognostic relevance of nuclear deoxyribonucleic acid ploidy studied by slide cytometry: an 8-year study. J Urol 1992;148:31-7.
9. Chiang PH, Huang MS, Tsai CJ, Tsai EM, Huang CH, Chiang CP. Transitional cell carcinoma of the renal pelvis and ureter in Taiwan. Cancer 1993;71:3988-92.
10. Lipponen P, Nordling S, Eskelinen MJ, Janhianen K, Terho R, Harjn E. Flow cytometry in comparison with mitotic index, predicting disease outcome in transitional-cell bladder cancer. Int J Cancer 1993;53:42-7.
11. Lipponen P, Eskelinen MJ. Proliferating-cell nuclear antigen (PCNA/cyclin) in transitional-cell bladder cancer and its prognostic value. Br J Cancer 1992;66:171-6.
12. Cheville JC, Terrell RB, Cohen MB. Use of proliferative markers Ki67 (MIB-1) and proliferating cell nuclear antigen (PC10) in transitional cell carcinoma of the renal pelvis. Mod Pathol 1994;7:794-800.
13. Rey A, Lara P, Redondo E, Valdéz E, Apolinario R. Ki67 proliferation index in tumors of the upper urinary tract as related to stablished prognostic factors and long-term survival. Arch Esp Urol. (In press).
14. Baker SJ, Markowitz S, Fearon ER, Willson JKV, Volgestein B. Suppression of human colorectal carcinoma cell growth by wild-type p53. Science 1990;249:912-5.
15. Mercer WE, Shields MT, Lin D, Apella E, Ullrich SJ. Growth supression induced by wild-type p53 protein is accompanied by selective down-regulation of proliferating-cell nuclear antigen expression. Proc Nat Acad Sci USA 1991; 88:1958-62.
16. Finlay CA, Hinds PW, Levine AJ. The p53 proto-oncogene can act as a suppressor of transformation. Cell 1989; 57:1083-93.
17. Lipponen P. Over-expression of p53 nuclear oncoprotein in transitional-cell bladder cancer and its prognostic value. Int J Cancer 1993;53:365-70.
18. Soini Y, Turpeenniemi-Hujanen T, Kamel D, Autro-Harmainen H, Risteli J, Risteli L, et al. p53 immunohistochemistry in transitional cell carcinoma and dysplasia of the urinary bladder correlates with disease free progression. Br J Cancer 1993;68:1029-35.
19. Cummings KB. Nephroureterectomy: rationale in the management of transitional cell carcinoma of the upper urinary tract. Urol Clin North Am 1991;23:569-78.
20. Tasca A, Zattoni F. The case for percutaneous approach to transitional cell carcinoma of the renal pelvis. J Urol 1990;143:901-4.
21. Gerber GS, Lyon ES. Endopyelotomy: patient selection, results, and complications. Urology 1994;43:2-10.
22. Cozad SC, Smalley SR, Austenfeld M, Noble M, Jennings S, Reymond R. Adjuvant radiotherapy in high stage transitional cell carcinoma of the renal pelvis and ureter. Int J Radiat Oncol Biol Phys 1992;24:743-5.
23. Kobayasi H, Obata K. Results of adjuvant chemotherapy for invasive urothelial cancer with lymph node metastasis. Cancer Chemother Pharmacol 1994;35(Suppl):S14-7.
24. Eastman JA, Huffman JL. Technique of mitomycin C instillation in the treatment of upper urinary tract urothelial tumors. J Urol 1993;150:324-5.
25. Behars OH, Henson DE, Hutter RVP, Kennedy BJ, editors. Manual for staging of cancer. 4th edition. Philadelphia: J.B. Lippincott, 1992;211-4.
26. Rosai J. Bladder and urethra. In: Rosai J. Ackerman's surgical pathology. Volume 1. 7th edition. St. Louis: C.V. Mosby, 1990;904-12.
27. Kaplan EI, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958;53:457-81.
28. Peto R, Pike MC, Armitage P, Breslow NE, Cox DR, Howard SV, et al. Design and analysis of randomized clinical trials requiring prolonged observation of each patient. Br J Cancer 1977;35:1-39.
29. Cox DR. Regression models and life-tables. JR Stat Soc (B) 1972;34:187-220.
30. Sidransky D, Von Eschenbach A, Tsai YC, Jones P, Summerhayes I, Marshall F, et al. Identification of p53-gene mutations in bladder cancers and urine samples. Science 1991;252:706-9.
31. Mostofi FK, Sobin LH, Torloni H. Histologic typing of urinary bladder tumors. In: International histological classification of tumors. Volume 10. Geneva: World Health Organization, 1973.
32. Lipponen PK, Eskelinen M. Expression of epidermal growth factor receptor in bladder cancer as related to established prognostic factors, oncoprotein (c-erbB-2, p53) expression and long-term prognosis. Br J Cancer 1994;69:1120-5.
33. Rodrigues NR, Rowan A, Smith MEF, Kerr IB, Bodmer WF, Cannon JV, et al. p53 mutations in colo-rectal cancer. Proc Natl Acad Sci USA 1990;87:7555-9.
34. Thompson AM, Anderson TJ, Condie A, Prossner J, Chetty U, Carter C, et al. p53 allele losses mutations and expression in breast cancer and their relationship to clinico-pathological parameters. Int J Cancer 1992;50:528-32.
35. Levine AJ, Momand J, Finlay CA. The p53 suppresor gene. Nature 1991;351:453-6.
36. Andersen JR, Ostri P, Jansen JE, Kristensen JK. A retrospective evaluation of 691 ureteroscopies: indications, procedures, success rate and complications. Urol Int 1993;51:191-7.
37. Grossman HB, Schwartz SL, Konnak JW. Ureteroscopic treatment of urothelial carcinoma of the ureter and renal pelvis. J Urol 1992;148:275-7.